Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Aged
Aged, 80 and over
Aging
Anti-HIV Agents
/ pharmacokinetics
Darunavir
/ pharmacokinetics
Drug Therapy, Combination
Female
HIV Infections
/ drug therapy
HIV Integrase Inhibitors
/ pharmacokinetics
Heterocyclic Compounds, 3-Ring
/ pharmacokinetics
Humans
Lamivudine
/ pharmacokinetics
Male
Middle Aged
Oxazines
/ pharmacokinetics
Piperazines
/ pharmacokinetics
Prospective Studies
Pyridones
/ pharmacokinetics
Viral Load
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 01 2020
01 01 2020
Historique:
pubmed:
7
9
2019
medline:
26
1
2021
entrez:
7
9
2019
Statut:
ppublish
Résumé
The pharmacokinetics of antiretroviral drugs may differ in elderly people living with HIV (PLWH) because of age-related physiological changes. We aimed to assess the pharmacokinetics of several antiretroviral drugs in aging PLWH enrolled in the Swiss HIV Cohort (SHCS). Full pharmacokinetic profiling nested in a multicenter, observational, prospective cohort study. Additional collection of single point pharmacokinetic data during SHCS follow-up visits (unselected PLWH). PLWH were eligible for the full pharmacokinetics investigation if they were over the age of 55 years, on a stable boosted darunavir-containing or dolutegravir-containing regimen. Single point measurements were prospectively collected during SHCS follow-up visits to compare antiretroviral drug exposure in aging (≥65 years) and younger (<65 years) PLWH. Nineteen PLWH with a median age of 64 years participated in the full pharmacokinetic investigations. Single point pharmacokinetic data were collected for 804 PLWH with a median age of 52 years. Boosted darunavir clearance was 40% lower in aging (≥65 years) compared with younger (<65 years) PLWH, consistent with other drugs predominantly metabolized by CYP3A. Dolutegravir exposure was similar between age groups whereas lamivudine exposure increased by 11% in aging PLWH. Median boosted darunavir, dolutegravir and lamivudine t1/2 were 148%, 45% and 32% higher in aging compared with younger PLWH. Advanced age did not affect boosted darunavir exposure to a clinically significant extent despite the observed high variability in exposure. Age minimally affected dolutegravir and lamivudine exposure. Thus, dose adjustment based on age is a priori not warranted.
Identifiants
pubmed: 31490233
doi: 10.1097/QAD.0000000000002372
pii: 00002030-202001010-00012
doi:
Substances chimiques
Anti-HIV Agents
0
HIV Integrase Inhibitors
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
Lamivudine
2T8Q726O95
dolutegravir
DKO1W9H7M1
Darunavir
YO603Y8113
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-108Références
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017; 4:e349–e356.
Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem A, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 2015; 15:810–818.
Smit M, Cassidy R, Cozzi-Lepri A, Quiros-Roldan E, Girardi E, Mammone A, et al. Projections of noncommunicable disease and healthcare costs among HIV-positive persons in Italy and the U.S.A.: a modelling study. PloS One 2017; 12:e0186638.
Watts G. Why the exclusion of older people from clinical research must stop. BMJ 2012; 344:e3445.
Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57:6–14.
Stader F, Siccardi M, Battegay M, Kinvig H, Penny MA, Marzolini C. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes. Clin Pharmacokinet 2019; 58:483–501.
Calza L, Colangeli V, Magistrelli E, Bussini L, Conti M, Ramazzotti E, et al. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. HIV Med 2017; 18:474–481.
Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, et al. AIDS Clinical Trials Protocol 5015 Team. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010; 26:635–643.
Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, et al. UK Collaborative HIV Cohort Study. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother 2013; 68:1354–1359.
Elliot ER, Wang X, Singh S, Simmons B, Vera JH, Miller RF, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis 2019; 68:87–95.
Cuzin L, Katlama C, Cotte L, Pugliese P, Cheret A, Bernaud C, et al. Dat’AIDS Study Group. Ageing with HIV: do comorbidities and polymedication drive treatment optimization?. HIV Med 2017; 18:395–401.
McNicholl IR, Gandhi M, Hare CB, Greene M, Pierluissi E. A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in Older HIV-positive patients. Pharmacotherapy 2017; 37:1498–1506.
Singh S, Bajorek B. Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy. Pharm Pract (Granada) 2014; 12:489.
Vigouroux C, Bastard JP, Capeau J. Emerging clinical issues related to management of multiorgan comorbidities and polypharmacy. Curr Opin HIV AIDS 2014; 9:371–378.
Lee HC, Tl Huang K, Shen WK. Use of antiarrhythmic drugs in elderly patients. J Geriatr Cardiol 2011; 8:184–194.
Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol 2019; 12:643–659.
Vass M, Hendriksen C. Medication for older people–aspects of rational therapy from the general practitioner's point of view. Z Gerontol Geriatr 2005; 38:190–195.
Aouri M, Calmy A, Hirschel B, Telenti A, Buclin T, Cavassini M, et al. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. J Mass Spectrom 2013; 48:616–625.
Courlet P, Spaggiari D, Cavassini M, Du Pasquier RA, Alves Saldanha S, Buclin T, et al. Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. Clin Mass Spec 2018; 8:8–20.
Fayet A, Beguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:1057–1069.
Denney WS, Duvvuri S, Buckeridge C. Simple, automatic noncompartmental analysis: the PKNCA R Package. J Pharmacokinet Pharmacodynamics 2015; 42:S65–S70.
Cheng H, Rogers JD, Sweany AE, Dobrinska MR, Stein EA, Tate AC, et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992; 9:1629–1633.
Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61:27–35.
Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br J Clin Pharmacol 1983; 15:303–309.
Arab-Alameddine M, Lubomirov R, Fayet-Mello A, Aouri M, Rotger M, Buclin T, et al. Swiss HIV Cohort Study. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. J Antimicrob Chemother 2014; 69:2489–2498.
Molto J, Xinarianos G, Miranda C, Pushpakom S, Cedeno S, Clotet B, et al. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. Clin Pharmacokinet 2013; 52:543–553.
Barcelo C, Aouri M, Courlet P, Guidi M, Braun DL, Gunthard HF, et al. Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother 2019; 74:2690–2697.
Zhang J, Hayes S, Sadler BM, Minto I, Brandt J, Piscitelli S, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol 2015; 80:502–514.
Francois P, Patrick M, Florence B, Marie-Claude G. Dolutegravir population pharmacokinetics in a real-life cohort of people living with HIV infection: a covariate analysis. Ther Drug Monit 2019; 41:444–451.
Bouazza N, Treluyer JM, Ghosn J, Hirt D, Benaboud S, Foissac F, et al. Evaluation of effect of impaired renal function on lamivudine pharmacokinetics. Br J Clin Pharmacol 2014; 78:847–854.
Moore KH, Yuen GJ, Hussey EK, Pakes GE, Eron JJ Jr, Bartlett JA. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 1999; 43:3025–3029.